John Bencich's most recent trade in Achieve Life Sciences Inc. was a trade of 5,000 Common Stock done at an average price of $3.7 . Disclosure was reported to the exchange on Aug. 16, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Grant, award, or other acquisition of securities at price $ 3.67 per share. | 16 Aug 2024 | 5,000 | 100,636 (0%) | 0% | 3.7 | 18,350 | Common Stock |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2024 | 25,000 | 0 | - | - | Performance Restricted Stock Unit (PRSU) | |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2024 | 25,000 | 101,724 (0%) | 0% | 0 | Common Stock | |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.51 per share. | 19 Apr 2024 | 6,088 | 95,636 (0%) | 0% | 4.5 | 27,457 | Common Stock |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 04 Mar 2024 | 10,000 | 10,000 | - | - | Common Stock Warrants (right to buy) | |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Purchase of securities on an exchange or from another person at price $ 4.58 per share. | 04 Mar 2024 | 10,000 | 76,724 (0%) | 0% | 4.6 | 45,850 | Common Stock |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2024 | 175,000 | 175,000 | - | - | Performance Restricted Stock Unit (PRSU) | |
| Achieve Life Sciences Inc | Bencich John | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2024 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Purchase of securities on an exchange or from another person at price $ 5.50 per share. | 30 May 2023 | 5,000 | 66,730 (0%) | 0% | 5.5 | 27,500 | Common Stock |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 7,500 | 0 | - | - | Performance Restricted Stock Unit (PRSU) | |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 7,500 | 63,557 (0%) | 0% | 0 | Common Stock | |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.29 per share. | 28 Apr 2023 | 1,827 | 61,730 (0%) | 0% | 8.3 | 15,146 | Common Stock |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.80 per share. | 21 Apr 2023 | 5,863 | 56,057 (0%) | 0% | 6.8 | 39,868 | Common Stock |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 100,000 | 100,000 | - | - | Performance Restricted Stock Unit (PRSU) | |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 18 Nov 2022 | 22,000 | 36,920 (0%) | 0% | - | Common Stock | |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 18 Nov 2022 | 11,000 | 11,000 | - | - | Common Stock Warrants (right to buy) | |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Grant, award, or other acquisition of securities at price $ 4.37 per share. | 16 Aug 2022 | 3,059 | 14,920 (0%) | 0% | 4.4 | 13,368 | Common Stock |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2022 | 7,500 | 7,500 | - | - | Performance Restricted Stock Unit (PRSU) | |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2022 | 7,500 | 13,688 (0%) | 0% | 0 | Common Stock | |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.43 per share. | 28 Apr 2022 | 1,827 | 11,861 (0%) | 0% | 7.4 | 13,575 | Common Stock |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 50,000 | 50,000 | - | - | Performance Restricted Stock Unit (PRSU) | |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2021 | 68 | 0 | - | - | Restricted Stock Unit (RSU) | |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2021 | 68 | 6,209 (0%) | 0% | 0 | Common Stock | |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.81 per share. | 17 Aug 2021 | 21 | 6,188 (0%) | 0% | 6.8 | 143 | Common Stock |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Purchase of securities on an exchange or from another person at price $ 7.00 per share. | 27 May 2021 | 6,000 | 6,141 (0%) | 0% | 7 | 42,000 | Common Stock |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Achieve Life Sciences Inc | John Bencich | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 15,000 | 15,000 | - | - | Performance Restricted Stock Unit (PRSU) |